ArticleNPJ cardiovascular health2025
Atrial cardiomyopathy in cardiac amyloidosis: clinical imaging and manifestations.
Article in NPJ cardiovascular health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Atrial Fibrillation in Infiltrative Cardiomyopathies: From Atrial Cardiomyopathy Imaging to Targeted Management-A Narrative Review.Medicina (Kaunas, Lithuania) · 2026Review
- Diagnostic Value of Native T1 and T2 Mapping in Differentiating Clinically Suspected Amyloidosis and Hypertrophic Cardiomyopathy.Diagnostics (Basel, Switzerland) · 2026Article
- Echocardiographic Markers of Cardiac Response to Therapy in Patients with Light Chain Amyloidosis.Echocardiography (Mount Kisco, N.Y.) · 2026Article
- Yield and predictors of conversion on serial amyloid nuclear SPECT/CT in at-risk populations for transthyretin cardiac amyloidosis.European heart journal. Imaging methods and practice · 2026Article
- The Arrhythmic Burden of Cardiac Amyloidosis: A Comprehensive Review.Heart views : the official journal of the Gulf Heart Association · 2026Review
- Structural characterization of atrial natriuretic peptide amyloid fibrils from patients with atrial fibrillation.Nature communications · 2025Article
- Advancing global cardiovascular research and clinical translation.NPJ cardiovascular health · 2025Article
- Wild-type transthyretin cardiac amyloidosis: a case of multisystemic involvement and review of literature.Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologieReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiac amyloidosis is a progressive infiltrative disease and an important cause of atrial arrhythmias, stroke and heart failure. Abnormal amyloid fibril deposition throughout the heart leads to a host of clinical manifestations and complications. Although atrial abnormalities are typically regarded as a consequence of ventricular diastolic dysfunction or atrial arrhythmias, there is emerging evidence that primary defects of atrial structure and function may be present. An atrial cardiomyopathy may be a sign of early cardiac disease, and an unrecognised independent marker of worse prognosis.This review summarizes current evidence specifically for atrial cardiomyopathy in cardiac amyloidosis, with a focus on imaging and clinical outcomes.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.